Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Attack
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 165 results found since Jan 2013.
India launches probe as Chinese company recalls BP drug
Valsartan is used to treat patients with high blood pressure in order to reduce complications such as heart attack and stroke. Both the importer and the manufacturer, Zhejiang Huahai Pharmaceuticals, will be issued notice soon.
Source: The Economic Times Healthcare and Biotech News - July 20, 2018 Category: Pharmaceuticals Source Type: news
WTC-Related PTSD May Up Risk for Stroke, MI in Clean-Up Crew
THURSDAY, July 19, 2018 -- World Trade Center-related post-traumatic stress disorder (PTSD) is a risk factor for myocardial infarction (MI) and stroke among workers involved in cleaning up the debris, according to a study published in the June issue...
Source: Drugs.com - Pharma News - July 19, 2018 Category: Pharmaceuticals Source Type: news
Increased Risk of MI, Ischemic Stroke After COPD Exacerbation
TUESDAY, June 19, 2018 -- For adults with chronic obstructive pulmonary disease (COPD), acute exacerbations are associated with increased risk of myocardial infarction and ischemic stroke, according to a study published online May 3 in the Annals of...
Source: Drugs.com - Pharma News - June 19, 2018 Category: Pharmaceuticals Source Type: news
New Advisory: Eat Fish Twice A Week To Lower Risk Of Heart Attack And Stroke -- What You Should Know
The American Heart Association released a new science advisory recommending non-fried fish twice a week to reduce risk of heart attack and stroke. Here ' s a breakdown of what you need to know.
Source: Forbes.com Healthcare News - May 20, 2018 Category: Pharmaceuticals Authors: David DiSalvo, Contributor Source Type: news
Amgen Receives European Commission Approval For Repatha ® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
New Indication Supports Amgen's Commitment to Reduce the Risk of Recurrent Cardiovascular Events Faced by Heart Attack and Stroke Survivors
Amgen Announces Efforts to Improve Repatha's Affordability Across Europe for Payers who Significantly Expand Patient Access
THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowerin...
Source: Amgen News Release - May 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Rate of MI, Stroke Higher After Respiratory Infection
FRIDAY, March 30, 2018 -- The risk for myocardial infarction (MI) or stroke remains higher after laboratory-confirmed Streptococcus pneumoniae or influenza, according to a study published March 21 in the European Respiratory Journal.
Charlotte...
Source: Drugs.com - Pharma News - March 30, 2018 Category: Pharmaceuticals Source Type: news
Social Isolation, Loneliness May Increase AMI, Stroke Risk
TUESDAY, March 27, 2018 -- Isolation and loneliness may be associated with increased risk of acute myocardial infarction (AMI) and stroke, according to a study published online March 27 in Heart.
Christian Hakulinen, Ph.D., from the University of...
Source: Drugs.com - Pharma News - March 27, 2018 Category: Pharmaceuticals Source Type: news
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER)
Amgen Continues to Work Closely With Payers on a Country-by-Country Basis to Ensure Access to Repatha for High-Risk Cardiovascular Patients
THOUSAN... Biopharmaceuticals, Cardiology, Regulatory Amgen, Repatha, evolocumab, myocardial infarction, stroke
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news
Amgen Receives Positive CHMP Opinion Recognizing That Repatha ® (evolocumab) Prevents Heart Attacks And Strokes
Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER)
Amgen Continues to Work Closely With Payers on a Country-by-Country Basis to Ensure Access to Repatha for High-Risk Cardiovascular Patients
THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, s...
Source: Amgen News Release - March 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
AstraZeneca has announced results from a new analysis of its landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating the risk of all-cause death (ACD), hospitalisation for heart failure (hHF), heart attack (myocardial infarction or MI) and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines.
Source: World Pharma News - March 14, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV death, myocardial infarction, or stroke) (HR 0.81; 95% CI, 0.7-0.95) and of 36% in coronary death (HR 0.64; 95% CI, 0.45-0.89) from treatment with Brilinta 60mg (ticagrelor), in combination with low dose aspirin, in people who had survived a heart attack and had stenosis (abnormal narrowing) in two or more coronary blood vessels, a condition known as multi-vessel disease (MVD).
Source: World Pharma News - February 7, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
11.12.17: Not intended for U.S. and UK Media
Bayer's rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery diseaseThe rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS studymehr ...
Source: Bayer IR Newsfeed: Events - December 10, 2017 Category: Pharmaceuticals Source Type: news
FDA Approves Amgen's Repatha ® (evolocumab) To Prevent Heart Attack And Stroke
Following FDA Priority Review, Repatha is the Only PCSK9 Inhibitor Approved to Reduce Risk of Heart Attack, Stroke and Coronary Revascularization
THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug Administration (FDA) approved Repatha® (evolocumab) as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.1
"We are pleased that the FDA made the inclusion of our outcomes data a priority ...
Source: Amgen News Release - December 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Why Eating Slowly This Thanksgiving Will Improve Your Long Term Health
As you sit down to Thanksgiving dinner to partake of turkey with all the trimmings, it ’s best to eat slowly. The risk includes not only weight gain, and elevated blood sugar, but your odds of developing metabolic syndrome, which can increase your risk of heart attack, stroke, and diabetes.
Source: Forbes.com Healthcare News - November 23, 2017 Category: Pharmaceuticals Authors: Robert Glatter, MD, Contributor Source Type: news
